Chinese Antibody Society

“#AntibodyPlus” is a novel concept coined in 2021 by the Chinese Antibody Society, and we believe this concept reflects the future trend of antibody-based therapeutics. To better explore the development of bispecific antibodies and antibody-drug conjugates (ADCs), the Chinese Antibody Society and its official journal, Antibody Therapeutics, will hold the 2024 mAbTalk Symposium on the first day of the 2024 Antibody Engineering & Therapeutics (AET) conference in San Diego, US. The symposium will take place on December 15, 2024 (Sunday), with the theme "Antibody Plus: Bispecific Antibodies and Antibody-Drug Conjugates." Registration for the 2024 mAbTalk Symposium is now open.?This event is free of charge and exclusive to all members of the Chinese Antibody Society. If you are not yet a member of the Chinese Antibody Society and would like to attend this event, you are welcome to register online to become a member of our society. https://lnkd.in/gjCEAVxM For registration, please send an e-mail to: [email protected] For sponsorship, please contact us via email at: [email protected].

This new paper regarding unexpected truncation of the commonly used GGGGS [(G4S)n] linkers looks very interesting to us. (G4S)n linkers are commonly used during the engineering of proteins because of their flexibility and resistance to proteases. However, unexpected truncation was observed in the linker of a bispecific antibody, which presented challenges in terms of production and quality. In this work, a bispecific antibody containing 5*G4S was investigated, and the truncation position of the linkers was confirmed. The investigation by the authors from Qilu Pharmaceuticals revealed that codon optimization, which can overcome the negative influence of a high repetition rate and high GC content in the (G4S)n linker, may reduce the truncation rate from 5–10% to 1–5%. Moreover, the probability of truncation when a shortened 3* or 4*G4S linker was used was much lower than that when a 5*G4S linker was used in mammalian cells. Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #linker #bispecific #bispecificantibody ##bispecificantibodies #bsab #bsabs

This most recent Nature Communications paper presents a pretrainable geometric graph neural network, GearBind, and explores its potential in in silico affinity maturation. Leveraging multi-relational graph construction, multi-level geometric message passing and contrastive pretraining on mass-scale, unlabeled protein structural data, GearBind outperforms previous state-of-the-art approaches on SKEMPI and an independent test set. These promising results reported in this paper underscore the utility of geometric deep learning and effective pretraining in macromolecule interaction modeling tasks. Three co-corresponding authors of this paper are Yanling Wu and Tianlei Ying at Fudan University and Jian Tang at BioGeometry and Mila - Quebec Artificial Intelligence Institute. Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #ai #ml #aritificialintelligence

Antibody Therapeutics just published a new review article (currently in accepted manuscript format) entitled "Practical Advice in the Development of a Lyophilized Protein Drug Product". This review offers practical advice on the critical aspects of lyophilized protein drug product development, including considerations across early and late stages of development, formulation strategies for enhancing protein stability and the efficiency of the lyophilization process, selection of primary containers and closures, and considerations in lyophilization cycle development. The corresponding author is Dr. Charlie Tang, a Principal Fellow at Regeneron. Other co-authors are Yuan Cheng, Huu Thuy Trang Duong, Qingyan Hu, and Mohammed Shameem. Open access to this paper at: https://lnkd.in/g-Ysae45 Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #lyophilizedprotein

This new open access article regarding a novel linker for ADC looks interesting to us. This study introduces an exolinker approach, repositioning the cleavable peptide linker at the exo position of the p-aminobenzylcarbamate moiety, as an advancement over conventional linear linkers. This design, which incorporates hydrophilic glutamic acid, addresses the limitations of the Val-Cit platform and improves the ADC in vivo profiles. In vitro and in vivo evaluations showed that exolinker ADCs reduced premature payload release, increased drug-to-antibody ratios, and avoided significant aggregation, even with hydrophobic payloads. Furthermore, the payload remained stably attached to the ADC even in the presence of enzymes like carboxylesterases and human neutrophil elastase, indicating the potential for a favorable safety profile. The corresponding author of this paper is Yutaka Matsuda at Ajinomoto Bio-Pharma Services. Open access to this paper at: https://lnkd.in/gZ4Hnmag Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate #linker #linkers

We highly recommend this new open access review article published in Nat Rev Drug Discov. This Review focuses on identifying key unsolved anti-drug antibody-related challenges and offers some pragmatic approaches towards addressing them. Examples are drawn mainly from antibodies, given that the majority of available clinical data are from this class of protein therapeutics. Plausible and seemingly tractable solutions are in sight for some immunogenicity problems, whereas other challenges will likely require completely new approaches. The two authors of this paper are prestigious Paul Carter and?Valerie Quarmby at Genentech. Open access to this excellent paper at: https://lnkd.in/eb8kVJgZ Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics

The design of antibody mimetics holds great promise for revolutionizing therapeutic interventions by offering alternatives to conventional antibody therapies. Structure-based computational approaches have emerged as indispensable tools in the rational design of those molecules, enabling the precise manipulation of their structural and functional properties. This open access review covers the main classes of designed antigen-binding motifs, as well as alternative strategies to develop tailored ones. Open access to this paper at: https://lnkd.in/gdpQ6Q7B Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics # antibodymimetics

The authors of new paper developed and decribe PLAbDab-nano, a nanobody complement to the Patent and Literature Antibody Database (PLAbDab). PLAbDab-nano is a self-updating, searchable repository containing ～5000 annotated VHH (variable heavy domain of the heavy chain) and VNAR (variable new antigen receptor) sequences. PLAbDab-nano is freely available as a searchable web server (https://lnkd.in/gjpDzJZJ). The corresponding author of this paper is Charlotte Deane at University of Oxford. Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #nanobody #nanobodies

Jazz Pharmaceuticals’?zanidatamab-hrii, with?brand?name?Ziihera,?gets FDA approve for?the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC). The??HERIZON-BTC-01 clinical trial?result shows a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months. zanidatamab-hrii?is a HER2-targeting?biparatopic?antibody contains binding arms of Roche’s?Trastuzumab and?Pertuzumab, which bind two non-overlap regions of HER2. Jazz Pharmaceuticals licensed the?molecule?from Zymeworks Inc.?in 2022 for?potential payments of up to?$1.76 billion, plus royalties on net sales.?Zymeworks Inc.?kept the ADC modality of the molecule,?zanidatamab?zovodotin, also known as ZW49, which is halted in clinical trial?by?Zymeworks?earlier?this?year. #antibodydiscovery?#bispecificantibody?#adc?#antibodydrugconjugation #oncology #cancer??#immunology??#immunotherapy??#antibodies?#mab #mabs https://lnkd.in/gmCBp6kU

This new paper published in Nature looks very interest to us. The following is the very informative abstract with novel and interesting findings. “The vertebrate adaptive immune system modifies the genome of individual B cells to encode antibodies that bind particular antigens1. In most mammals, antibodies are composed of heavy and light chains that are generated sequentially by recombination of V, D (for heavy chains), J and C gene segments. Each chain contains three complementarity-determining regions (CDR1–CDR3), which contribute to antigen specificity. Certain heavy and light chains are preferred for particular antigens. Here we consider pairs of B cells that share the same heavy chain V gene and CDRH3 amino acid sequence and were isolated from different donors, also known as public clonotypes23,24. We show that for naive antibodies (those not yet adapted to antigens), the probability that they use the same light chain V gene is around 10%, whereas for memory (functional) antibodies, it is around 80%, even if only one cell per clonotype is used. This property of functional antibodies is a phenomenon that we call light chain coherence. We also observe this phenomenon when similar heavy chains recur within a donor. Thus, although naive antibodies seem to recur by chance, the recurrence of functional antibodies reveals surprising constraint and determinism in the processes of V(D)J recombination and immune selection. For most functional antibodies, the heavy chain determines the light chain.” Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics